---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-070444"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2023-06-12T23:59:59+00:00"
generated_at: "2026-06-14T02:48:42.368845+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma prices $4M at-the-market offering, appoints new director, extends loan interest-only period

## Summary
- Gross proceeds of ~$4M from 1.74M shares and pre-funded warrants at $1.84/unit; offering expected to close June 13, 2023.
- Abhinav Jain of Nantahala Capital appointed to Board; Board increases from 4 to 5 members.
- Company to focus on Rx segment, de-emphasize or monetize Consumer Health segment, suspend pipeline programs.
- Closing of offering extends interest-only period on $15M Avenue Capital term loan through maturity in January 2025.
- Common warrants (Tranche A & B) exercisable at $1.59/share for up to 4.35M shares; potential additional $7M.

## SEC filing metadata
- accession: 0001104659-23-070444
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2023-06-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000110465923070444/0001104659-23-070444-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000110465923070444/tm2318372d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-070444
- JSON: https://secwatch.observer/filing/0001104659-23-070444.json
- Plain text: https://secwatch.observer/filing/0001104659-23-070444.txt

## Key facts
- Executive change
  Abhinav Jain was appointed as Director at AYTU BIOPHARMA, INC.
  - Action: appointed
  - Role: Director
  source text: Pursuant to the terms of the Purchase Agreement, effective as of the closing of the Offering, the size of the Board will be increased from four (4) to five (5), and Abhinav Jain shall be appointed to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000110465923070444/0001104659-23-070444-index.htm
- Material Agreements
  AYTU BIOPHARMA, INC entered into Purchase Agreement with certain investors valued at approximately $4 million (effective 2023-06-08).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors
  - Value: approximately $4 million
  - Effective: 2023-06-08
  source text: On June 8, 2023, Aytu BioPharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors named therein (the “Purchasers”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000110465923070444/0001104659-23-070444-index.htm
- Material Agreements
  AYTU BIOPHARMA, INC entered into PAA with Maxim Group LLC (effective 2023-06-08).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Maxim Group LLC
  - Effective: 2023-06-08
  source text: amed therein (the “Purchasers”), and a placement agency agreement (the “PAA”) with Maxim Group LLC (the “Placement Agent”), pursuant to which the Company agreed to issue and sell to investors in the offering (the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000110465923070444/0001104659-23-070444-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.